NO315274B1 - Fremgangsmåte for fremstilling av en polysakkaridgel- blanding, polysakkaridgel-blandinger, samt anvendelser derav - Google Patents
Fremgangsmåte for fremstilling av en polysakkaridgel- blanding, polysakkaridgel-blandinger, samt anvendelser derav Download PDFInfo
- Publication number
- NO315274B1 NO315274B1 NO19980213A NO980213A NO315274B1 NO 315274 B1 NO315274 B1 NO 315274B1 NO 19980213 A NO19980213 A NO 19980213A NO 980213 A NO980213 A NO 980213A NO 315274 B1 NO315274 B1 NO 315274B1
- Authority
- NO
- Norway
- Prior art keywords
- cross
- polysaccharide
- linking
- gel
- mixture
- Prior art date
Links
- 150000004676 glycans Chemical class 0.000 title claims abstract description 65
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 65
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 64
- 238000000034 method Methods 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims description 24
- 238000004132 cross linking Methods 0.000 claims abstract description 59
- 238000006243 chemical reaction Methods 0.000 claims abstract description 45
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 21
- 238000001879 gelation Methods 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 239000007864 aqueous solution Substances 0.000 claims abstract description 5
- 229920000642 polymer Polymers 0.000 claims description 20
- 102000003951 Erythropoietin Human genes 0.000 claims description 13
- 108090000394 Erythropoietin Proteins 0.000 claims description 13
- 229940105423 erythropoietin Drugs 0.000 claims description 13
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 13
- 229940088623 biologically active substance Drugs 0.000 claims description 12
- 229920002674 hyaluronan Polymers 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 11
- 229960003160 hyaluronic acid Drugs 0.000 claims description 11
- 239000012736 aqueous medium Substances 0.000 claims description 9
- 239000013543 active substance Substances 0.000 claims description 7
- 229940088597 hormone Drugs 0.000 claims description 7
- 239000005556 hormone Substances 0.000 claims description 7
- 230000000069 prophylactic effect Effects 0.000 claims description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- 238000005728 strengthening Methods 0.000 claims description 6
- 102000055006 Calcitonin Human genes 0.000 claims description 5
- 108060001064 Calcitonin Proteins 0.000 claims description 5
- 229920001605 Dextranomer Polymers 0.000 claims description 5
- 230000002378 acidificating effect Effects 0.000 claims description 5
- 229960004015 calcitonin Drugs 0.000 claims description 5
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 5
- 150000002118 epoxides Chemical class 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical class C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 4
- 125000000524 functional group Chemical group 0.000 claims description 4
- 239000002609 medium Substances 0.000 claims description 4
- SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 claims description 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 3
- 229920001503 Glucan Polymers 0.000 claims description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000003405 delayed action preparation Substances 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 230000008020 evaporation Effects 0.000 claims description 3
- 229960002442 glucosamine Drugs 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 229920000331 Polyhydroxybutyrate Polymers 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 10
- 230000000977 initiatory effect Effects 0.000 abstract description 2
- 150000004804 polysaccharides Polymers 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 79
- 239000000243 solution Substances 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 5
- 239000004926 polymethyl methacrylate Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 238000009739 binding Methods 0.000 description 3
- 229960002864 dextranomer Drugs 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000008154 viscoelastic solution Substances 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000001361 achilles tendon Anatomy 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 229920000249 biocompatible polymer Polymers 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010074604 Epoetin Alfa Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- USDJGQLNFPZEON-UHFFFAOYSA-N [[4,6-bis(hydroxymethylamino)-1,3,5-triazin-2-yl]amino]methanol Chemical compound OCNC1=NC(NCO)=NC(NCO)=N1 USDJGQLNFPZEON-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- LDVRMNJZLWXJPL-JKQNMTHDSA-N calcitonin (human synthetic) Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 LDVRMNJZLWXJPL-JKQNMTHDSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010981 drying operation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000007863 gel particle Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000030175 lameness Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 108010032806 molgramostim Proteins 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000012254 powdered material Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 108010068072 salmon calcitonin Proteins 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
- C08J2305/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/503,323 US5827937A (en) | 1995-07-17 | 1995-07-17 | Polysaccharide gel composition |
| PCT/SE1996/000684 WO1997004012A1 (fr) | 1995-07-17 | 1996-05-28 | Composition de gel a base de polysaccharide |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO980213D0 NO980213D0 (no) | 1998-01-16 |
| NO980213L NO980213L (no) | 1998-03-16 |
| NO315274B1 true NO315274B1 (no) | 2003-08-11 |
Family
ID=24001615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19980213A NO315274B1 (no) | 1995-07-17 | 1998-01-16 | Fremgangsmåte for fremstilling av en polysakkaridgel- blanding, polysakkaridgel-blandinger, samt anvendelser derav |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US5827937A (fr) |
| EP (1) | EP0839159B1 (fr) |
| JP (1) | JP3094074B2 (fr) |
| KR (1) | KR100314488B1 (fr) |
| CN (1) | CN1083849C (fr) |
| AT (1) | ATE204000T1 (fr) |
| BR (2) | BR9609534B1 (fr) |
| CA (1) | CA2226488C (fr) |
| CZ (1) | CZ290755B6 (fr) |
| DE (2) | DE839159T1 (fr) |
| DK (1) | DK0839159T3 (fr) |
| EA (1) | EA001500B1 (fr) |
| ES (1) | ES2161368T3 (fr) |
| GR (1) | GR3037065T3 (fr) |
| HU (1) | HU220257B (fr) |
| MX (1) | MX9800484A (fr) |
| NO (1) | NO315274B1 (fr) |
| NZ (1) | NZ312229A (fr) |
| PL (1) | PL188071B1 (fr) |
| PT (1) | PT839159E (fr) |
| SI (1) | SI0839159T1 (fr) |
| SK (1) | SK282431B6 (fr) |
| TR (1) | TR199800072T1 (fr) |
| UA (1) | UA48980C2 (fr) |
| WO (1) | WO1997004012A1 (fr) |
Families Citing this family (160)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7968110B2 (en) * | 1992-02-11 | 2011-06-28 | Merz Aesthetics, Inc. | Tissue augmentation material and method |
| US7060287B1 (en) * | 1992-02-11 | 2006-06-13 | Bioform Inc. | Tissue augmentation material and method |
| US6537574B1 (en) | 1992-02-11 | 2003-03-25 | Bioform, Inc. | Soft tissue augmentation material |
| US6193994B1 (en) * | 1996-05-23 | 2001-02-27 | Samyang Corporation | Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof |
| TW586934B (en) * | 1997-05-19 | 2004-05-11 | Sumitomo Pharma | Immunopotentiating composition |
| US7192984B2 (en) * | 1997-06-17 | 2007-03-20 | Fziomed, Inc. | Compositions of polyacids and polyethers and methods for their use as dermal fillers |
| DK0999854T3 (da) | 1997-07-29 | 2004-02-09 | Alcon Mfg Ltd | Omskiftelige viskoelastiske systemer, der indeholder galactomannanpolymerer og -borater |
| GB9902412D0 (en) | 1999-02-03 | 1999-03-24 | Fermentech Med Ltd | Process |
| GB9902652D0 (en) | 1999-02-05 | 1999-03-31 | Fermentech Med Ltd | Process |
| US8188043B2 (en) * | 1999-07-28 | 2012-05-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Nicotine in therapeutic angiogenesis and vasculogenesis |
| KR100721752B1 (ko) | 2000-01-24 | 2007-05-25 | 쿠라레 메디카루 가부시키가이샤 | 수팽윤성 고분자 겔 및 그 제조법 |
| SE0004928D0 (sv) * | 2000-12-29 | 2000-12-29 | Apbiotech Ab | A method for the manufacturing of porous material |
| FR2819722B1 (fr) * | 2001-01-19 | 2006-11-24 | Corneal Ind | Utilisation de l'acide hyaluronique ou d'au moins l'un de ses sels dans le cadre d'un traitemnet chirurgical de la presbytie |
| US8580290B2 (en) | 2001-05-08 | 2013-11-12 | The Board Of Regents Of The University Of Oklahoma | Heparosan-based biomaterials and coatings and methods of production and use thereof |
| US20070078435A1 (en) * | 2001-06-14 | 2007-04-05 | Corbett Stone | Tissue augmentation methods using a medical injection apparatus |
| ES2294180T3 (es) | 2001-12-11 | 2008-04-01 | Ceapro Inc. | Composiciones de beta-glucano de cereales, metodos de preparacion y usos de las mismas. |
| KR20040009891A (ko) * | 2002-07-26 | 2004-01-31 | 주식회사 엘지생명과학 | 히알루론산의 유도체 겔 및 그 제조방법 |
| US7816316B2 (en) * | 2002-11-21 | 2010-10-19 | Chugai Seiyaku Kabushiki Kaisha | Sustained release drug carrier |
| FR2861734B1 (fr) | 2003-04-10 | 2006-04-14 | Corneal Ind | Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus |
| AU2003901834A0 (en) | 2003-04-17 | 2003-05-01 | Clearcoll Pty Ltd | Cross-linked polysaccharide compositions |
| JP2004323454A (ja) * | 2003-04-25 | 2004-11-18 | Chisso Corp | 薬剤 |
| JP2007500027A (ja) * | 2003-07-30 | 2007-01-11 | アンタイス エス．エイ． | 生物医学的な使用のための複合マトリックス |
| JP4511470B2 (ja) | 2003-10-29 | 2010-07-28 | 帝人株式会社 | ヒアルロン酸化合物、そのハイドロゲルおよび関節軟骨損傷治療用材料 |
| EP1683812B1 (fr) * | 2003-11-14 | 2014-11-12 | Chugai Seiyaku Kabushiki Kaisha | Microparticules de polysaccharides reticulees et leur procede de production |
| US8124120B2 (en) * | 2003-12-22 | 2012-02-28 | Anika Therapeutics, Inc. | Crosslinked hyaluronic acid compositions for tissue augmentation |
| US8524213B2 (en) * | 2003-12-30 | 2013-09-03 | Genzyme Corporation | Polymeric materials, their preparation and use |
| FR2865737B1 (fr) * | 2004-02-03 | 2006-03-31 | Anteis Sa | Gel reticule biocompatible |
| US20050226936A1 (en) * | 2004-04-08 | 2005-10-13 | Q-Med Ab | Method of soft tissue augmentation |
| SE0401182D0 (sv) * | 2004-05-05 | 2004-05-05 | Q Med Ab | Novel use of a viscoelastic composition |
| WO2005113608A1 (fr) | 2004-05-20 | 2005-12-01 | Mentor Corporation | Méthode pour lier covalemment l’hyaluronan et le chitosan |
| TW200612991A (en) | 2004-09-07 | 2006-05-01 | Chugai Pharmaceutical Co Ltd | Process for producing water-soluble hyaluronic acid modification |
| CN101056891B (zh) * | 2004-11-15 | 2010-05-26 | 株式会社资生堂 | 交联透明质酸凝胶的制备方法 |
| US20060105022A1 (en) * | 2004-11-15 | 2006-05-18 | Shiseido Co., Ltd. | Process for preparing crosslinked hyaluronic acid gel |
| SI1835923T1 (sl) | 2004-12-30 | 2014-01-31 | Genzyme Coroporation | ReĹľimi za intraartikularno viskosuplementacijo |
| US20060263415A1 (en) | 2005-05-05 | 2006-11-23 | Sensient Flavors Inc. | Production of beta-glucans and mannans |
| US20070003584A1 (en) * | 2005-06-16 | 2007-01-04 | Russell Anderson | Liquid crystal polymer syringes and containers and methods of use for long term storage of filler materials |
| KR101250846B1 (ko) * | 2005-07-04 | 2013-04-05 | 주식회사 엘지생명과학 | 히알루론산 가교물의 제조방법 |
| US20070102010A1 (en) * | 2005-10-07 | 2007-05-10 | Lemperle Stefan M | Naso-pharyngeal tissue engineering |
| CN100379763C (zh) * | 2006-01-12 | 2008-04-09 | 武汉大学 | 交联茯苓多糖及其制备方法和用途 |
| US20070184087A1 (en) | 2006-02-06 | 2007-08-09 | Bioform Medical, Inc. | Polysaccharide compositions for use in tissue augmentation |
| US20070212385A1 (en) * | 2006-03-13 | 2007-09-13 | David Nathaniel E | Fluidic Tissue Augmentation Compositions and Methods |
| DE102006013594A1 (de) * | 2006-03-22 | 2007-09-27 | Biopolymer Gmbh & Co. Kg | Quervernetzte Gele von Hyaluronsäure und deren Verwendung |
| EP2543340A1 (fr) * | 2006-05-19 | 2013-01-09 | Trustees Of Boston University | Nouveaux polymères hydrophiles utilisés en tant que gels et lubrifiants à usage médical |
| FR2909285A1 (fr) * | 2006-12-01 | 2008-06-06 | Anteis Sa | "utilisation d'un gel anti-adhesif et anti fibrotique" |
| WO2008136536A1 (fr) | 2007-05-01 | 2008-11-13 | National University Corporation Tokyo Medical And Dental University | Gel hybride comprenant un dérivé de l'acide hyaluronique réticulé chimiquement, et composition pharmaceutique l'utilisant |
| WO2008143680A1 (fr) * | 2007-05-16 | 2008-11-27 | Medicis Pharmaceutical Corporation | Méthodes pour identifier des surfaces de la peau d'un sujet qui semblent manquer de volume |
| US8658148B2 (en) | 2007-06-22 | 2014-02-25 | Genzyme Corporation | Chemically modified dendrimers |
| FR2918377B1 (fr) * | 2007-07-05 | 2010-10-08 | Estelle Piron | Gel co-reticule de polysaccharides |
| US20090023631A1 (en) * | 2007-07-18 | 2009-01-22 | Lorenc Z Paul | Composition and Method of Use for Soft Tissue Augmentation/Drug Delivery |
| WO2009018546A1 (fr) | 2007-08-02 | 2009-02-05 | Medicis Pharmaceutical Corporation | Procédé d'application d'un produit de comblement des rides injectable |
| US20090204101A1 (en) * | 2007-08-20 | 2009-08-13 | Wortzman Mitchell S | Method of applying an injectable filler |
| US8691957B2 (en) | 2007-09-28 | 2014-04-08 | Shiseido Company, Ltd. | Swellable crosslinked hyaluronan powder and method for producing the same |
| WO2009044403A2 (fr) * | 2007-10-05 | 2009-04-09 | Juvenis Ltd. | Compositions polymères biodégradables injectables pour la réparation et l'augmentation des tissus mous |
| KR101577471B1 (ko) | 2007-11-16 | 2015-12-14 | 알러간, 인코포레이티드 | 자색반병의 치료를 위한 조성물 및 방법 |
| US20090143348A1 (en) * | 2007-11-30 | 2009-06-04 | Ahmet Tezel | Polysaccharide gel compositions and methods for sustained delivery of drugs |
| US8394782B2 (en) | 2007-11-30 | 2013-03-12 | Allergan, Inc. | Polysaccharide gel formulation having increased longevity |
| US9925209B2 (en) | 2008-03-19 | 2018-03-27 | The Board Of Regents Of The University Of Oklahoma | Heparosan-polypeptide and heparosan-polynucleotide drug conjugates and methods of making and using same |
| US9687559B2 (en) * | 2008-03-19 | 2017-06-27 | The Board Of Regents Of The University Of Oklahoma | Heparosan polymers and methods of making and using same for the enhancement of therapeutics |
| GB2459438B (en) * | 2008-04-10 | 2010-10-06 | Kythera Biopharmaceuticals Inc | Systems and methods for transdermal photo-polymerization |
| US8932622B2 (en) * | 2008-06-03 | 2015-01-13 | Actamax Surgical Materials, Llc | Tissue coating for preventing undesired tissue-to-tissue adhesions |
| US8450475B2 (en) | 2008-08-04 | 2013-05-28 | Allergan, Inc. | Hyaluronic acid-based gels including lidocaine |
| JP5722217B2 (ja) | 2008-09-02 | 2015-05-20 | アラーガン・ホールディングス・フランス・ソシエテ・パール・アクシオン・サンプリフィエＡｌｌｅｒｇａｎ Ｈｏｌｄｉｎｇｓ Ｆｒａｎｃｅ Ｓ．Ａ．Ｓ． | ヒアルロン酸および／またはその誘導体の糸、その作製方法、ならびにその使用 |
| CN101445566B (zh) * | 2008-12-11 | 2011-05-04 | 彭秀兰 | No增放剂精氨酸氨基多糖及其生产方法 |
| US9173975B2 (en) * | 2009-04-24 | 2015-11-03 | Ingeneron, Inc. | Reparative cell delivery via hyaluronic acid vehicles |
| IT1395392B1 (it) | 2009-08-27 | 2012-09-14 | Fidia Farmaceutici | Geli viscoelastici come nuovi filler |
| US8273725B2 (en) | 2009-09-10 | 2012-09-25 | Genzyme Corporation | Stable hyaluronan/steroid formulation |
| EP2498764B1 (fr) | 2009-11-09 | 2017-09-06 | Spotlight Technology Partners LLC | Hydrogels fragmentés |
| CA2780294C (fr) | 2009-11-09 | 2018-01-16 | Spotlight Technology Partners Llc | Hydrogels a base de polysaccharide |
| US9114188B2 (en) | 2010-01-13 | 2015-08-25 | Allergan, Industrie, S.A.S. | Stable hydrogel compositions including additives |
| US20110172180A1 (en) | 2010-01-13 | 2011-07-14 | Allergan Industrie. Sas | Heat stable hyaluronic acid compositions for dermatological use |
| WO2011110894A2 (fr) | 2010-03-12 | 2011-09-15 | Allergan Industrie Sas | Composition fluide pour l'amélioration d'états cutanés |
| HUE043344T2 (hu) | 2010-03-22 | 2019-08-28 | Allergan Inc | Térhálósított hidrogélek lágy szövet növelésére |
| CN102933615B (zh) * | 2010-06-08 | 2015-08-12 | 陶氏环球技术有限责任公司 | 制备粒状可逆交联的聚合物材料的方法 |
| CA2805008C (fr) | 2010-07-12 | 2015-05-12 | Shin Poong Pharmaceutical Co., Ltd. | Composition de remplissage pour l'augmentation tissulaire comprenant un hydrogel d'acide hyaluronique croise avec la diamine d'alkylene |
| US9005605B2 (en) | 2010-08-19 | 2015-04-14 | Allergan, Inc. | Compositions and soft tissue replacement methods |
| US8883139B2 (en) | 2010-08-19 | 2014-11-11 | Allergan Inc. | Compositions and soft tissue replacement methods |
| US8889123B2 (en) | 2010-08-19 | 2014-11-18 | Allergan, Inc. | Compositions and soft tissue replacement methods |
| US20130303695A1 (en) * | 2010-09-02 | 2013-11-14 | Heather Sheardown | Hyaluronic acid-containing biopolymers |
| FR2968996B1 (fr) | 2010-12-17 | 2013-04-12 | Anteis Sa | Formulation aqueuse injectable sterile utilisee en ophtalmologie |
| EP2484387A1 (fr) * | 2011-02-03 | 2012-08-08 | Q-Med AB | Composition d'acide hyaluronique |
| CA2830654A1 (fr) | 2011-03-31 | 2012-10-04 | Galderma Research & Development | Compositions comprenant un produit de charge et au moins un materiau a base de silice bioresorbable et biodegradable |
| WO2012146031A1 (fr) * | 2011-04-26 | 2012-11-01 | 北京爱美客生物科技有限公司 | Gel composite d'acide hyaluronique et d'hydroxypropylméthylcellulose et procédé de production de celui-ci |
| US9408797B2 (en) | 2011-06-03 | 2016-08-09 | Allergan, Inc. | Dermal filler compositions for fine line treatment |
| US9393263B2 (en) | 2011-06-03 | 2016-07-19 | Allergan, Inc. | Dermal filler compositions including antioxidants |
| US20130096081A1 (en) | 2011-06-03 | 2013-04-18 | Allergan, Inc. | Dermal filler compositions |
| CA3133676A1 (fr) | 2011-06-03 | 2012-12-06 | Allergan Industrie, Sas | Compositions de remplissage dermique comprenant des antioxydants |
| WO2013016571A1 (fr) | 2011-07-28 | 2013-01-31 | Harbor Medtech, Inc. | Produits réticulés de tissu humain ou animal, leurs procédés de fabrication et leur utilisation |
| US20130244943A1 (en) | 2011-09-06 | 2013-09-19 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
| US9662422B2 (en) | 2011-09-06 | 2017-05-30 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
| EP2581079B1 (fr) * | 2011-10-11 | 2016-12-07 | BioPolymer GmbH & Co. KG | Combinaison d'acide hyaluronique et de prilocaïne |
| ITAN20110138A1 (it) | 2011-10-12 | 2012-01-11 | Regenyal Lab S R L | Sintesi di un gel iniettabile multifasico a base di acido ialuronico monofasico libero e reticolato e di acido ialuronico bifasico associato con idrossiapatite con inibitore della ialuronidasi microincapsulato. |
| KR20140059238A (ko) * | 2011-11-11 | 2014-05-15 | 미바 메디컬 아이엔시. | 주사 시술용 보형물 |
| ES2645082T3 (es) | 2012-03-12 | 2017-12-04 | The Regents Of The University Of California | Métodos y composiciones de tratamiento de heridas y reducción del riesgo de hernias incisionales |
| KR101240518B1 (ko) | 2012-03-26 | 2013-03-11 | 주식회사 제네웰 | 생체 적합성 고분자를 이용한 이식용 재료 |
| BR112014024291B1 (pt) | 2012-03-30 | 2022-07-05 | The Board Of Regents Of The University Of Oklahoma | Método para a produção de forma recombinante de um polímero de heparosan com alto peso molecular, uso do referido polímero para aumento de tecido, polinucleotídeo isolado e composição de material biológico compreendendo o referido polímero |
| CN102614111B (zh) * | 2012-04-05 | 2013-11-06 | 苏州豫源生物医药有限公司 | 氨基葡萄糖的凝胶剂及其制备方法 |
| ITMI20120732A1 (it) | 2012-05-03 | 2013-11-04 | B S Srl | Polisaccaridi reticolati a memoria di forma |
| ITPD20120173A1 (it) | 2012-05-31 | 2013-12-01 | Fidia Farmaceutici | "nuovo sistema di rilascio di proteine idrofobiche" |
| CN104395348B (zh) | 2012-06-15 | 2019-07-30 | 莫茨药物股份两合公司 | 制备基于透明质酸的组合物的方法 |
| JP5840107B2 (ja) | 2012-06-17 | 2016-01-06 | コスメディ製薬株式会社 | ヒアルロン酸ゲル及びその製造方法 |
| BR112015016734A2 (pt) | 2013-01-11 | 2017-07-11 | Carbylan Therapeutics Inc | composições estabilizadas compreendendo ácido hialurônico |
| CN103146003A (zh) * | 2013-03-06 | 2013-06-12 | 上海其胜生物制剂有限公司 | 一种低温二次交联透明质酸钠凝胶的制备方法 |
| KR101869988B1 (ko) * | 2013-03-27 | 2018-06-21 | 주식회사 엘지화학 | 점탄성 히알루론산 가교물 제조용 조성물, 및 이를 이용하여 얻은 히알루론산 가교물 |
| UA120037C2 (uk) | 2013-05-15 | 2019-09-25 | Зе Боард Оф Трастеес Оф Зе Леланд Станфорд Джуніор Юніверсіті | Застосування гепаринзв'язувального епідермального фактора росту білка для загоєння хронічної перфорації барабанної перетинки |
| WO2014198406A1 (fr) | 2013-06-11 | 2014-12-18 | Anteis S.A. | Procédé de réticulation de l'acide hyaluronique, procédé de préparation d'un hydrogel injectable, hydrogel obtenu et utilisation de l'hydrogel obtenu |
| CA2916330A1 (fr) * | 2013-06-28 | 2014-12-31 | Galderma S.A. | Procede pour preparer un produit reticule d'acide hyaluronique |
| EP3013865B1 (fr) * | 2013-06-28 | 2019-10-23 | Galderma S.A. | Procédé de fabrication d'un produit façonné à base d'acide hyaluronique réticulé |
| EP3017808B1 (fr) | 2013-07-03 | 2022-07-13 | Ritapharma, Co., Ltd. | Gel d'acide hyaluronique hydrosoluble et procédé pour le produire |
| ES2653549T3 (es) | 2013-09-30 | 2018-02-07 | Galderma S.A. | Funcionalización y reticulación de ácido hialurónico en un paso |
| KR101459070B1 (ko) | 2013-12-09 | 2014-11-17 | (주) 뉴메딕 | 지속성을 갖는 히알루론산 겔 조성물 |
| AR099900A1 (es) | 2014-04-01 | 2016-08-24 | Merz Pharma Gmbh & Co Kgaa | Rellenos para tejidos blandos con polisacáridos con persistencia mejorada, kit, procedimiento, uso |
| US20170210829A1 (en) * | 2014-05-29 | 2017-07-27 | Galderma S.A. | Cross-linked polymer mixture of hyaluronic acid and dextran grafted with cyclodextrins and uses thereof |
| JP2017517601A (ja) * | 2014-05-29 | 2017-06-29 | ガルデルマ エス．エー． | デキストランによりグラフト化された架橋ヒアルロン酸 |
| WO2016030516A1 (fr) | 2014-08-29 | 2016-03-03 | Galderma S.A. | Bdde énantiopur ou énantioenrichi et son utilisation comme agent de réticulation dans la fabrication de produits réticulés |
| WO2016051219A1 (fr) | 2014-09-30 | 2016-04-07 | Allergan Industrie, Sas | Compositions d'hydrogel stables pourvues d'additifs |
| EP3204017A4 (fr) * | 2014-10-08 | 2018-06-27 | Andreas Voigt | Systèmes de biopolymères réticulés hydrophiles micronisés et leur procédé de fabrication |
| MX2017008105A (es) | 2014-12-18 | 2018-03-06 | Galderma Sa | Injerto de ciclodextrina mediante enlaces amida a un acido hialuronico reticulado a eter y sus usos. |
| EP3040118A1 (fr) | 2014-12-29 | 2016-07-06 | Galderma S.A. | Hydrogels de chondroïtine réticulée d'éther et leur utilisation pour des applications de tissu mou |
| EP3040348A1 (fr) | 2014-12-29 | 2016-07-06 | Galderma S.A. | Copolymère greffé |
| EP3040117A1 (fr) | 2014-12-29 | 2016-07-06 | Galderma S.A. | Hydrogels de sulfate de chondroïtine réticulée par éther et leur utilisation pour des applications de tissu mou |
| WO2016128783A1 (fr) | 2015-02-09 | 2016-08-18 | Allergan Industrie Sas | Compositions et méthodes pour améliorer l'apparence de la peau |
| US10004824B2 (en) | 2015-05-11 | 2018-06-26 | Laboratoires Vivacy | Compositions comprising at least one polyol and at least one anesthetic |
| WO2016192760A1 (fr) | 2015-05-29 | 2016-12-08 | Galderma S.A. | Hydrogels mélangés d'acide hyaluronique et de dextrane |
| US20180169297A1 (en) | 2015-06-12 | 2018-06-21 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Injectable composition of factor vii and fillers |
| FR3037797B1 (fr) | 2015-06-24 | 2018-08-17 | Kylane Laboratoires Sa | Procede de preparation d'un hydrogel reticule injectable; hydrogel obtenu; utilisation de l'hydrogel obtenu |
| US9737395B2 (en) | 2015-06-26 | 2017-08-22 | Phi Nguyen | Systems and methods for reducing scarring |
| US20180177707A1 (en) | 2015-06-30 | 2018-06-28 | Merz Pharma Gmbh & Co. Kgaa | Method of preparing a composition based on hyaluronic acid |
| KR20170025778A (ko) | 2015-08-31 | 2017-03-08 | 대화제약 주식회사 | 항산화제를 포함하는 생체 적합성 고분자 히알루론산 유도체 및 그 히알루론산의 가교결합물 |
| KR101720426B1 (ko) | 2015-09-01 | 2017-04-14 | (주)시지바이오 | 히알루론산 조성물 및 그의 제조방법 |
| CN105126157B (zh) * | 2015-09-17 | 2018-02-09 | 爱美客技术发展股份有限公司 | 医用可注射粘合凝胶及其制备方法 |
| FR3044557B1 (fr) | 2015-12-07 | 2017-12-01 | Benedicte Vincente Gavard Molliard Tauzin | Nouvelle composition injectable; procede de preparation de ladite composition; utilisation de ladite composition |
| FR3047666A1 (fr) | 2016-02-15 | 2017-08-18 | Benedicte Vincente Gavard Molliard Tauzin | Composition injectable; procede de preparation de ladite composition; utilisation de ladite composition |
| KR101866310B1 (ko) | 2016-05-31 | 2018-06-11 | 주식회사 글랜젠 | 생체 내 지속성 및 항산화 작용이 향상된 진피 충전재 조성물 및 이의 제조방법 |
| EP3475312B1 (fr) | 2016-06-23 | 2020-05-27 | Galderma S.A. | Acide hyaluronique réticulé greffé complexé avec des substances actives de médicaments et leurs utilisations |
| WO2018024795A1 (fr) | 2016-08-03 | 2018-02-08 | Galderma Research & Development | Procédé de réticulation de glycosaminoglycanes |
| CN110023341B (zh) | 2016-08-03 | 2021-06-25 | 高德美研究及发展公司 | 使糖胺聚糖交联的方法 |
| EP3515511A1 (fr) | 2016-09-21 | 2019-07-31 | Nestlé Skin Health SA | Gel d'acide hyaluronique à cation zinc divalent |
| AR110125A1 (es) | 2016-11-07 | 2019-02-27 | Croma Pharma Ges M B H | Compuestos poliméricos que liberan sulfuro de hidrógeno |
| EP3494146A1 (fr) | 2016-12-23 | 2019-06-12 | Galderma Research & Development | Glycosaminoglycanes à double réticulation |
| WO2018122342A1 (fr) | 2016-12-29 | 2018-07-05 | Nestlé Skin Health Sa | Vésicules multilamellaires micro- ou nanoparticulaires, compositions les comprenant et leur procédé d'utilisation dans les soins de la peau |
| WO2018122344A1 (fr) | 2016-12-29 | 2018-07-05 | Nestlé Skin Health Sa | Composition comprenant un acide hyaluronique (ah) réticulé en combinaison avec un ah de faible poids moléculaire et/ou un agent stimulant la synthèse d'ah endogène |
| WO2018122343A1 (fr) | 2016-12-29 | 2018-07-05 | Nestlé Skin Health Sa | Vésicules micro- ou nanoparticulaires comprenant de l'acide hyaluronique réticulé, compositions les comprenant et leur méthode d'utilisation dans les soins de la peau |
| IT201700008651A1 (it) | 2017-01-26 | 2018-07-26 | Beauty System Pharma Ltd | Acido ialuronico reticolato con agenti reticolanti di tipo naturale o semisintetico |
| CN108721206B (zh) * | 2017-04-14 | 2021-11-09 | 常州药物研究所有限公司 | 治疗膀胱输尿管返流、压力性尿失禁和大便失禁的组合物及其制备方法 |
| WO2018220283A1 (fr) | 2017-05-29 | 2018-12-06 | Kh Medtech Sarl | Composition injectable sterile contenant de l'acide hyaluronique reticule et de l'articaine |
| WO2019002371A1 (fr) | 2017-06-28 | 2019-01-03 | Nestlé Skin Health Sa | Gel de glycosaminoglycane avec tampon bis-tris |
| WO2019001784A1 (fr) | 2017-06-28 | 2019-01-03 | Nestlé Skin Health Sa | Gel d'acide hyaluronique avec un cation divalent |
| WO2019121694A1 (fr) | 2017-12-22 | 2019-06-27 | Nestlé Skin Health Sa | Compositions injectables d'acide hyaluronique réticulé et de bupivacaïne, et utilisations associées |
| EP3787702A1 (fr) | 2018-05-03 | 2021-03-10 | CollPlant Ltd. | Charges dermiques et applications de celles-ci |
| KR102392812B1 (ko) | 2018-07-06 | 2022-04-29 | 주식회사 엘지화학 | 높은 점탄성 및 응집성을 동시에 갖는 히알루론산 필러 |
| RU2770541C1 (ru) | 2018-07-10 | 2022-04-18 | ЭлДжи КЕМ, ЛТД. | Наполнитель с гиалуроновой кислотой, имеющий высокую способность лифтинга и низкую силу инъекции |
| KR20200046649A (ko) | 2018-10-25 | 2020-05-07 | (주)뉴크레이티브랩 | 혼합상 히알루론산 제조방법 |
| TWI739241B (zh) | 2018-12-20 | 2021-09-11 | 南韓商Ｌｇ化學股份有限公司 | 具優異填料性質之包含玻尿酸水凝膠之填料、其製法及其用途 |
| TWI797405B (zh) | 2018-12-21 | 2023-04-01 | 南韓商Ｌｇ化學股份有限公司 | 具有經改善之填充性質的包含玻尿酸水凝膠之填料 |
| US20220160936A1 (en) | 2019-04-02 | 2022-05-26 | Volumina Medical Sa | Composition comprising a cross-linked polyol |
| TR201922907A2 (tr) * | 2019-12-31 | 2021-07-26 | Vsy Biyoteknoloji Ve Ilac Sanayi Anonim Sirketi | Osteoartri̇t tedavi̇si̇ i̇çi̇n yeni̇ bi̇r vi̇skoelasti̇k formülasyonu ve bunun üreti̇m yöntemi̇ |
| KR102425496B1 (ko) | 2020-05-08 | 2022-07-26 | 주식회사 종근당 | 고탄성, 고점도 및 고유효 가교율을 갖는 히알루론산 가교체, 및 이의 제조방법 |
| WO2023038463A1 (fr) | 2021-09-09 | 2023-03-16 | 선바이오(주) | Transition sol-gel d'hydrogel de peg à 6 bras au cours du temps |
| IT202100032111A1 (it) | 2021-12-22 | 2023-06-22 | Fidia Farm Spa | Nuovi sostituti biocompatibili dell’umor vitreo |
| WO2023148619A1 (fr) | 2022-02-01 | 2023-08-10 | Galderma Holding SA | Procédés de production d'hydrogels à base acide hyaluronique réticulés |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4197846A (en) * | 1974-10-09 | 1980-04-15 | Louis Bucalo | Method for structure for situating in a living body agents for treating the body |
| US4716224A (en) * | 1984-05-04 | 1987-12-29 | Seikagaku Kogyo Co. Ltd. | Crosslinked hyaluronic acid and its use |
| GB8412423D0 (en) * | 1984-05-16 | 1984-06-20 | Allied Colloids Ltd | Polymeric compositions |
| SE442820B (sv) * | 1984-06-08 | 1986-02-03 | Pharmacia Ab | Gel av tverbunden hyaluronsyra for anvendning som glaskroppssubstitut |
| US4863907A (en) * | 1984-06-29 | 1989-09-05 | Seikagaku Kogyo Co., Ltd. | Crosslinked glycosaminoglycans and their use |
| US4582865A (en) * | 1984-12-06 | 1986-04-15 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
| US5128326A (en) * | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
| SE458525B (sv) * | 1985-05-23 | 1989-04-10 | Pharmacia Ab | Foerfarande foer tvaerbindning av en poroes agar- eller agarosgel |
| SE452469B (sv) * | 1986-06-18 | 1987-11-30 | Pharmacia Ab | Material bestaende av en tverbunden karboxylgrupphaltig polysackarid och forfarande vid framstellning av detsamma |
| US4803075A (en) * | 1986-06-25 | 1989-02-07 | Collagen Corporation | Injectable implant composition having improved intrudability |
| IT1198449B (it) * | 1986-10-13 | 1988-12-21 | F I D I Farmaceutici Italiani | Esteri di alcoli polivalenti di acido ialuronico |
| US4767463A (en) * | 1987-04-15 | 1988-08-30 | Union Carbide Corporation | Glycosaminoglycan and cationic polymer combinations |
| US5017229A (en) * | 1990-06-25 | 1991-05-21 | Genzyme Corporation | Water insoluble derivatives of hyaluronic acid |
| US5007940A (en) * | 1989-06-09 | 1991-04-16 | American Medical Systems, Inc. | Injectable polymeric bodies |
| US5143724A (en) * | 1990-07-09 | 1992-09-01 | Biomatrix, Inc. | Biocompatible viscoelastic gel slurries, their preparation and use |
| US5246698A (en) * | 1990-07-09 | 1993-09-21 | Biomatrix, Inc. | Biocompatible viscoelastic gel slurries, their preparation and use |
| US5633001A (en) * | 1993-03-19 | 1997-05-27 | Medinvent | Composition and a method for tissue augmentation |
-
1995
- 1995-07-17 US US08/503,323 patent/US5827937A/en not_active Expired - Lifetime
-
1996
- 1996-05-28 JP JP09506592A patent/JP3094074B2/ja not_active Expired - Lifetime
- 1996-05-28 DE DE0839159T patent/DE839159T1/de active Pending
- 1996-05-28 CN CN96195523A patent/CN1083849C/zh not_active Expired - Lifetime
- 1996-05-28 EP EP96923119A patent/EP0839159B1/fr not_active Expired - Lifetime
- 1996-05-28 UA UA98020826A patent/UA48980C2/uk unknown
- 1996-05-28 BR BRPI9609534-2A patent/BR9609534B1/pt active IP Right Grant
- 1996-05-28 PL PL96324608A patent/PL188071B1/pl unknown
- 1996-05-28 TR TR1998/00072T patent/TR199800072T1/xx unknown
- 1996-05-28 MX MX9800484A patent/MX9800484A/es unknown
- 1996-05-28 SK SK61-98A patent/SK282431B6/sk not_active IP Right Cessation
- 1996-05-28 CZ CZ1998129A patent/CZ290755B6/cs not_active IP Right Cessation
- 1996-05-28 BR BRPI9609534A patent/BRPI9609534B8/pt unknown
- 1996-05-28 SI SI9630349T patent/SI0839159T1/xx unknown
- 1996-05-28 WO PCT/SE1996/000684 patent/WO1997004012A1/fr active IP Right Grant
- 1996-05-28 AT AT96923119T patent/ATE204000T1/de active
- 1996-05-28 DE DE69614391T patent/DE69614391T2/de not_active Expired - Lifetime
- 1996-05-28 HU HU9901714A patent/HU220257B/hu unknown
- 1996-05-28 KR KR1019980700337A patent/KR100314488B1/ko not_active IP Right Cessation
- 1996-05-28 DK DK96923119T patent/DK0839159T3/da active
- 1996-05-28 EA EA199800133A patent/EA001500B1/ru not_active IP Right Cessation
- 1996-05-28 CA CA002226488A patent/CA2226488C/fr not_active Expired - Lifetime
- 1996-05-28 NZ NZ312229A patent/NZ312229A/xx not_active IP Right Cessation
- 1996-05-28 ES ES96923119T patent/ES2161368T3/es not_active Expired - Lifetime
- 1996-05-28 PT PT96923119T patent/PT839159E/pt unknown
-
1998
- 1998-01-16 NO NO19980213A patent/NO315274B1/no not_active IP Right Cessation
-
2001
- 2001-10-30 GR GR20010401937T patent/GR3037065T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO315274B1 (no) | Fremgangsmåte for fremstilling av en polysakkaridgel- blanding, polysakkaridgel-blandinger, samt anvendelser derav | |
| MXPA98000484A (en) | Composition in polisacar gel | |
| CN106310383B (zh) | 一种可注射骨修复水凝胶及其制备方法 | |
| JP3337472B2 (ja) | 創傷治癒剤 | |
| CN107708675A (zh) | 假塑性微凝胶基质的组合物和试剂盒 | |
| US8771734B2 (en) | Sustained-release hydrogel preparation | |
| BR0007985B1 (pt) | processo para a preparação de derivados multiplamente reticulados do ácido hialurÈnico (ha), ha multiplamente reticulado, ha reticulado em um ou mais polìmeros diferentes de ha, ha reticulado em um segundo polìmero, produto, e, uso de um derivado de ha multiplamente reticulado. | |
| Chak et al. | A review on collagen based drug delivery systems | |
| JP2007537249A (ja) | 荷電ポリマーを含むゲル組成物 | |
| BR112013012772B1 (pt) | Preparação e/ou formulação de proteínas reticuladas com polissacarídeos | |
| KR20140059238A (ko) | 주사 시술용 보형물 | |
| KR20150040817A (ko) | 선택적 중합성 조성물 및 생체 내에서 사용 방법 | |
| WO2020122707A1 (fr) | Hydrogel pour libération directionnelle in vivo de médicament | |
| Doǧan et al. | Controlled release of EGF and bFGF from dextran hydrogels in vitro and in vivo | |
| CN110713727A (zh) | 一种低温制备的胶原蛋白水凝胶、其制备方法及应用 | |
| CN111743857A (zh) | 一种壳聚糖水凝胶及其制备方法 | |
| CN115282339B (zh) | 一种交联透明质酸/羟基磷灰石可注射材料、制备方法及应用 | |
| JPH07503001A (ja) | コラーゲンマイクロカプセル含有注射可能組成物 | |
| AU700215C (en) | Polysaccharide gel composition | |
| Kim et al. | Chitosan-based delivery system for tissue regeneration and chemotherapy | |
| JP2000239305A (ja) | 生体吸収性薬物担体 | |
| KR20070031931A (ko) | 하전된 폴리머를 포함하는 겔 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |